Strikingly, recent preclinical and preliminary clinical data demonstrated an outstanding clinical efficacy of 3rd-generation EGFR-TKIs in patients with advanced NSCLC harboring T790M [18–23]. Here, EGFR is linked to non-small cell lung carcinoma.